What hypercoagulable workup is indicated for an 86‑year‑old female with recurrent deep vein thrombosis and pulmonary embolism despite being on apixaban (Eliquis) 2.5 mg twice daily and aspirin, considering her multiple comorbidities?

Recurrent VTE on Apixaban 2.5 mg BID: Escalate to Full-Dose Anticoagulation and Investigate for Antiphospholipid Syndrome

This 86-year-old patient experiencing recurrent DVT/PE while on apixaban 2.5 mg BID represents anticoagulation failure and requires immediate escalation to full therapeutic-dose anticoagulation (apixaban 5 mg BID or switch to alternative agent) while pursuing a targeted hypercoagulable workup focused primarily on antiphospholipid syndrome.

Critical First Step: Fix the Anticoagulation Problem

The patient is on apixaban 2.5 mg BID, which is a reduced dose intended only for secondary prevention after completing at least 6 months of full-dose therapy 1. This is NOT a treatment dose for acute recurrent VTE. The FDA-approved treatment regimen for acute DVT/PE is apixaban 10 mg BID for 7 days, then 5 mg BID 1.

Immediate action:

• Escalate to apixaban 5 mg BID (or 10 mg BID for 7 days if treating as acute event)
• Discontinue aspirin - it adds bleeding risk without meaningful benefit when on therapeutic anticoagulation 2
• Consider switching to LMWH or warfarin given DOAC failure, particularly if antiphospholipid syndrome is suspected 3

The Hypercoagulable Workup: Be Selective

In an 86-year-old with recurrent VTE on anticoagulation, do NOT order a comprehensive thrombophilia panel. Age alone makes hereditary thrombophilias clinically irrelevant, and most results won't change management.

Priority Testing (Order These):

1. Antiphospholipid Syndrome Panel - This is the critical diagnosis to rule out:

• Lupus anticoagulant
• Anticardiolipin antibodies (IgG and IgM)
• Anti-β2-glycoprotein I antibodies (IgG and IgM)

Rationale: APS is the most important acquired thrombophilia that causes DOAC failure and recurrent thrombosis despite anticoagulation 4, 5, 6. If positive, requires confirmation testing at 12 weeks and mandates switch to warfarin or LMWH, as DOACs are less effective in APS 3, 5.

2. Active Malignancy Screening:

• Age-appropriate cancer screening if not up to date
• Consider CT chest/abdomen/pelvis if unexplained weight loss, anemia, or other red flags
• CBC, comprehensive metabolic panel

Rationale: Occult malignancy is a persistent risk factor for recurrent VTE and would mandate extended anticoagulation 2.

3. Medication Adherence and Drug Interactions:

• Verify actual adherence (pill counts, pharmacy records)
• Review for P-gp and strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's wort) that reduce apixaban levels 1

Do NOT Order These (Low Yield in This Context):

• Factor V Leiden, Prothrombin G20210A mutation - Irrelevant at age 86; first VTE would have occurred decades earlier 7
• Protein C, Protein S, Antithrombin deficiency - Same reasoning; also unreliable while on anticoagulation
• Homocysteine, MTHFR mutation - Not actionable

Management Algorithm

Step 1: Immediate Anticoagulation Adjustment

• If treating as acute recurrent event: Apixaban 10 mg BID × 7 days → 5 mg BID
• If already past acute phase: Apixaban 5 mg BID immediately
• Stop aspirin

Step 2: Send Targeted Labs

• Antiphospholipid antibody panel (before switching off DOAC if possible, though lupus anticoagulant may be affected)
• CBC, CMP, age-appropriate cancer screening

Step 3: Risk Stratification for Anticoagulant Choice

If antiphospholipid antibodies are positive:

• Switch to warfarin (target INR 2.5-3.0) or LMWH 3, 5
• DOACs have documented failure in APS 4, 5, 6

If active cancer is identified:

• Consider continuing full-dose apixaban 5 mg BID (recent data supports this) 8
• Alternative: LMWH if GI or GU malignancy with high bleeding risk

If no clear cause identified (true DOAC failure):

• Switch to LMWH 1.5 mg/kg daily or BID 3, 9
• Alternative: Warfarin with target INR 2.5-3.0 (or 3.0-4.0 if recurrent despite therapeutic INR)

Step 4: Duration of Therapy

This patient requires lifelong anticoagulation given recurrent unprovoked VTE 2. The 2021 CHEST guidelines strongly recommend extended-phase anticoagulation for unprovoked VTE 2.

Critical Pitfalls to Avoid

1. Assuming 2.5 mg BID is therapeutic: This is the most common error. The reduced dose is only for secondary prevention after 6+ months of full-dose therapy, NOT for active treatment 1.

2. Ordering extensive thrombophilia panels in elderly patients: Factor V Leiden and other hereditary thrombophilias don't present at age 86. Focus on acquired causes 7.

3. Missing antiphospholipid syndrome: This is the one diagnosis that absolutely changes management and explains DOAC failure 4, 5, 6. The ASH guidelines specifically suggest LMWH over DOACs for breakthrough VTE 3.

4. Continuing aspirin with therapeutic anticoagulation: Adds bleeding risk without proven benefit in VTE 2.

5. Not checking for drug interactions: P-gp/CYP3A4 inducers can dramatically reduce apixaban levels 1.

Quality of Life and Mortality Considerations

At age 86 with multiple comorbidities, the balance between preventing fatal PE (mortality benefit) versus bleeding risk (morbidity) is delicate. However, recurrent VTE despite anticoagulation carries extremely high mortality risk and justifies aggressive anticoagulation escalation 10. The reduced-dose regimen she's currently on was never intended for this scenario and represents under-treatment 2, 1.

If bleeding risk is prohibitive with full-dose anticoagulation, consider IVC filter placement, though this should be a last resort given her need for lifelong anticoagulation.